{"url_path":"/sec/flgt/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1674930/0001674930-26-000028-index.html","accession_number":"0001674930-26-000028","cik":"0001674930","ticker":"FLGT","issuer_name":"Fulgent Genetics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1674930/0001674930-26-000028-index.html","primary_entity_key":"0001674930","primary_entity_name":"Fulgent Genetics, Inc."},"word_count":101,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 1, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, previously released on May 21, 2026. A copy of the Company’s press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K."}